Skip to main content
AMPLIA THERAPEUTICS LIMITED logo

AMPLIA THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · ATX ISIN · AU0000023822 ASX Professional, scientific and technical activities
Open in API
Filings indexed 670 across all filing types
Latest filing 2026-05-18 Regulatory Filings
Country AU Australia
Listing ASX ATX

About AMPLIA THERAPEUTICS LIMITED

https://ampliatx.com

Amplia Therapeutics Limited is a clinical-stage pharmaceutical company focused on the development of small molecule inhibitors of Focal Adhesion Kinase (FAK). The company's primary asset, narmafotinib (AMP945), is a potent and highly selective FAK inhibitor designed to treat solid tumors and fibrotic diseases. Narmafotinib is currently undergoing clinical evaluation for the treatment of advanced pancreatic cancer, where it aims to reduce the fibrotic stroma that protects tumors and limits the effectiveness of standard-of-care chemotherapy. Amplia is also investigating the application of its FAK inhibitor platform in idiopathic pulmonary fibrosis (IPF). The company's pipeline includes AMP886, which targets FAK as well as VEGFR3 and FLT3. The core business strategy involves leveraging targeted kinase inhibition to address significant unmet needs in oncology and chronic fibrosis.

Recent filings

Filing Released Lang Actions
Amplia Launches First Stage of Pivotal Narmafotinib Trial 2 pages 135.2KB
Regulatory Filings Classification · 30% confidence The document is an ASX release announcing the launch of a new Phase 2b clinical trial of narmafotinib. It does not contain financial statements, earnings data, management changes, or proxy materials. It is not a formal report (e.g., annual or interim report) but a corporate announcement filed with the exchange. As it does not fit any specific category, it falls under the general Regulatory Filings fallback category.
2026-05-18 English
Application for quotation of securities - ATX 6 pages 18.9KB
Share Issue/Capital Change Classification · 91% confidence The document is an ASX Appendix 2A “Application for quotation of securities” notifying the exchange of new ordinary shares being quoted following the exercise of options under an employee incentive scheme. It does not present financial results, management discussion, or meeting materials but specifically reports a capital change (conversion of options into issued shares). Therefore it is classified as a Share Issue/Capital Change.
2026-05-11 English
Notice under Section 708A(5)(e) of the Corporations Act 1
Share Issue/Capital Change Classification · 85% confidence The document is an ASX release titled “Notice under Section 708A(5)(e) of the Corporations Act” that informs investors the company has issued 240,385 fully paid ordinary shares upon exercise of zero-exercise-price options. It is an announcement of a new share issuance (capital change), matching the Share Issue/Capital Change category (SHA).
2026-05-11 English
Amplia and ANZGOG announce Ovarian Cancer Study 3 pages 164.7KB
Regulatory Filings
2026-05-07 English
Quarterly Activities/Appendix 4C Cash Flow Report 8 pages 373.3KB
Regulatory Filings
2026-04-27 English
ACCENT Trial Mature Data Presented at AACR Conference 20 pages 1.7MB
Investor Presentation Classification · 82% confidence The document is an ASX release announcing “Mature data from Amplia’s ACCENT trial ... presented at the AACR annual meeting” and includes a full slide deck with trial design, results, and graphics. It is not reporting financial results (so not ER or IR), nor is it a short notice of publication. It is a detailed presentation of clinical data targeted at investors and stakeholders. This fits the “Investor Presentation” (IP) category.
2026-04-21 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.